Zanubrutinib (new indication: marginal zone lymphoma (MLZ), ≥ 1 prior anti-CD20-antibody-based therapy)



  • Active Substance: Zanubrutinib
  • Name: Brukinsa®
  • Therapeutic area: Marginal zone lymphoma (MZL)
  • Pharmaceutical company: BeiGene Germany GmbH


Time table:

  • Start: 15.12.2022
  • Publication of assessment: 15.03.2023
  • End of public hearing: 05.04.2023
  • Final decision by G-BA: middle of June 2023


Comparative therapy:

  • A patient-individual therapy depending on previous therapies, disease course (including duration of remission since last therapy) and general condition